Telix Pharmaceuticals Management
Management criteria checks 3/4
Telix Pharmaceuticals' CEO is Chris Behrenbruch, appointed in Jul 2023, has a tenure of less than a year. total yearly compensation is A$1.02M, comprised of 49% salary and 51% bonuses, including company stock and options. directly owns 7.03% of the company’s shares, worth A$295.70M. The average tenure of the management team and the board of directors is 1.6 years and 6.6 years respectively.
Key information
Chris Behrenbruch
Chief executive officer
AU$1.0m
Total compensation
CEO salary percentage | 49.0% |
CEO tenure | less than a year |
CEO ownership | 7.0% |
Management average tenure | 1.6yrs |
Board average tenure | 6.6yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Dec 31 2023 | AU$1m | AU$499k | AU$5m |
Sep 30 2023 | n/a | n/a | -AU$21m |
Jun 30 2023 | n/a | n/a | -AU$48m |
Mar 31 2023 | n/a | n/a | -AU$76m |
Dec 31 2022 | AU$865k | AU$422k | -AU$104m |
Sep 30 2022 | n/a | n/a | -AU$111m |
Jun 30 2022 | n/a | n/a | -AU$119m |
Mar 31 2022 | n/a | n/a | -AU$100m |
Dec 31 2021 | AU$620k | AU$374k | -AU$81m |
Sep 30 2021 | n/a | n/a | -AU$70m |
Jun 30 2021 | n/a | n/a | -AU$59m |
Mar 31 2021 | n/a | n/a | -AU$52m |
Dec 31 2020 | AU$421k | AU$295k | -AU$45m |
Sep 30 2020 | n/a | n/a | -AU$40m |
Jun 30 2020 | n/a | n/a | -AU$36m |
Mar 31 2020 | n/a | n/a | -AU$32m |
Dec 31 2019 | AU$460k | AU$317k | -AU$28m |
Sep 30 2019 | n/a | n/a | -AU$23m |
Jun 30 2019 | n/a | n/a | -AU$19m |
Mar 31 2019 | n/a | n/a | -AU$16m |
Dec 31 2018 | AU$380k | AU$280k | -AU$14m |
Sep 30 2018 | n/a | n/a | -AU$12m |
Jun 30 2018 | n/a | n/a | -AU$10m |
Mar 31 2018 | n/a | n/a | -AU$8m |
Dec 31 2017 | AU$303k | AU$211k | -AU$6m |
Compensation vs Market: Chris's total compensation ($USD653.20K) is below average for companies of similar size in the Australian market ($USD2.11M).
Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.
CEO
Chris Behrenbruch (47 yo)
less than a year
Tenure
AU$1,018,461
Compensation
Dr. Christian P. Behrenbruch, also known as Chris, BEng (Hons), J.D., Ph.D. DPhil (Oxon), MBA (TRIUM), JD (Melb), FIEAust, GAICD, is Co-Founder, Chief Executive Officer and Managing Director of Telix Pharm...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | less than a year | AU$1.02m | 7.03% A$ 295.7m | |
Group Chief Financial Officer | 1.7yrs | AU$713.90k | 0.0020% A$ 82.9k | |
Chief Medical Advisor & Non-Executive Director | no data | AU$43.00k | 6.86% A$ 288.7m | |
Group Chief Commercial Officer | 2.9yrs | AU$902.90k | 0.038% A$ 1.6m | |
Group Chief Operating Officer | less than a year | no data | no data | |
Chief Scientist | 2.9yrs | AU$167.76k | no data | |
Chief Information Officer | 1.3yrs | no data | no data | |
Senior Vice President of Corporate Communications & Investor Relations | 2.8yrs | no data | no data | |
Senior VP of Global Governance | 1.3yrs | no data | no data | |
Group General Counsel | 1.6yrs | no data | no data | |
Vice President of Sales | no data | no data | no data | |
Senior Vice President of Global People & Culture | 1.6yrs | no data | no data |
1.6yrs
Average Tenure
Experienced Management: TLX's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder | 7.3yrs | AU$1.02m | 7.03% A$ 295.7m | |
Chief Medical Advisor & Non-Executive Director | 7.3yrs | AU$43.00k | 6.86% A$ 288.7m | |
Independent Non-Executive Chairman | 6.6yrs | AU$188.28k | 0.35% A$ 14.6m | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Independent Non-Executive Director | 6.6yrs | AU$103.30k | 1.1% A$ 46.2m | |
Independent Non-Executive Director | 5.8yrs | AU$111.56k | 0.18% A$ 7.6m | |
Member of the Scientific Advisory Board | no data | no data | 0.54% A$ 22.9m | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data | |
Member of the Scientific Advisory Board | no data | no data | no data |
6.6yrs
Average Tenure
65yo
Average Age
Experienced Board: TLX's board of directors are considered experienced (6.6 years average tenure).